Screener
Rigel Pharmaceuticals RIGL Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Principal payments of term loans | (7,500) | — |
| Net proceeds from issuance of common stock under equity plans | 321 | 484 |
| Repurchases of common stock in connection with employee tax withholding on RSU vesting | (3,740) | — |
| Net cash (used in) provided by financing activities | (10,919) | 484 |
| Net decrease in cash, cash equivalents and restricted cash | (16,169) | (10,961) |
| Cash, cash equivalents, and restricted cash at beginning of period | 40,637 | 56,746 |
| Cash, cash equivalents, and restricted cash at end of period | $24,468 | $45,785 |
| Supplemental disclosure of cash flow information |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's financing cash flow?
- Rigel Pharmaceuticals (RIGL) reported financing cash flow of -$10.92M in Q1 2026.
- How has Rigel Pharmaceuticals's financing cash flow changed year-over-year?
- Rigel Pharmaceuticals's financing cash flow decreased by 2356.0% year-over-year, from $484K to -$10.92M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Rigel Pharmaceuticals's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude